About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
T-cell Activation, Deactivation and Control and the Impact of Cancer Immunotherapy
By
Leonard Calabrese
58 Videos
287 views
December 19, 2017
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Related Content
AUTOPLAY
ON
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
04:16
Luke Fletcher
Efficacy and Safety of Asciminib in Ph+ CML
50:34
Scripps MD Anderson Cancer Center
The Cure of Leukemias in the Next Decade: An Optimist’s View
Feat.
H. Kantarjian
06:00
2024 Clinical Case Studies
Clinical Case Review: A Not-So-Sweet Case of Vulvar Ulceration
Feat.
A. Geisler
30:05
Cleveland Clinic Respiratory Institute
Diagnosis and Staging of Lung Cancer in the Era of Advanced Diagnost…
Feat.
F. Almeida
19:10
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Treat AML at MD Anderson Cancer Center
Feat.
H. Kantarjian
08:18
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…
Feat.
A. Zhou
09:51
i3 Health
MRD Testing in Leukemias: When Negativity Is a Positive Thing
Feat.
N. S. Raje
16:25
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: The New ELN Laboratory Recommendations for the Diagnosis …
Feat.
N. Cross
40:52
Houston Methodist Hospital
Respiratory Tract, EBUS, Molecular Biomarker Testing in Non-Small Ce…
Feat.
S. Roy-Chowdhuri
27:28
UChicago Medicine
AML: Current Treatment Landscape and Key Recent Updates
Feat.
A. Patel
13:16
ASH 2022 Conference Coverage
Experts Discuss Key Updates in CLL
Feat.
S. O'Brien,
C. Coombs
09:27
ASH 2022 Conference Coverage
MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…
Feat.
M. McMullin
27:14
2024 Clinical Case Studies
Clinical Case Review: Cutaneous T Cell Lymphoma in the Patch Test Cl…
Feat.
J. Murase
19:15
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: CML - Are We Doing It Right?
Feat.
J. Cortés
17:30
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Rational TKI Choice in CML
Feat.
M. Deininger
10:35
Alan Skarbnik
Learnings From the ELEVATE-TN Phase 3 Trial: Acalabrutinib+/-Obinutu…
16:59
MyCancerHaven
Experts Discuss Current and Future Management of AML
Feat.
R. Vij,
N. Daver
16:25
Northwestern Medicine Oncology and Hematology
Diagnosis and Goals of Therapy in PV
Feat.
B. Stein
17:47
The University of Alabama at Birmingham School of Medicine
Treating CML Patients With TKI Resistance vs. TKI Intolerance
Feat.
O. Jamy
